These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2017 related articles for article (PubMed ID: 29530936)

  • 1. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 2. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
    Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
    Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
    [No Abstract]   [Full Text] [Related]  

  • 4. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
    Carvajal-Hausdorf D; Altan M; Velcheti V; Gettinger SN; Herbst RS; Rimm DL; Schalper KA
    J Immunother Cancer; 2019 Mar; 7(1):65. PubMed ID: 30850021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.
    Varki V; Ioffe OB; Bentzen SM; Heath J; Cellini A; Feliciano J; Zandberg DP
    Cancer Immunol Immunother; 2018 May; 67(5):805-814. PubMed ID: 29484464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
    Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
    Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
    [No Abstract]   [Full Text] [Related]  

  • 8. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
    Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
    Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.
    Yim J; Koh J; Kim S; Song SG; Ahn HK; Kim YA; Jeon YK; Chung DH
    Eur J Cancer; 2020 Jul; 133():74-85. PubMed ID: 32447027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.
    O'Shaughnessy MJ; Murray KS; La Rosa SP; Budhu S; Merghoub T; Somma A; Monette S; Kim K; Corradi RB; Scherz A; Coleman JA
    Clin Cancer Res; 2018 Feb; 24(3):592-599. PubMed ID: 28954788
    [No Abstract]   [Full Text] [Related]  

  • 14. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
    Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
    Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.
    Arina A; Karrison T; Galka E; Schreiber K; Weichselbaum RR; Schreiber H
    Cancer Immunol Res; 2017 Feb; 5(2):127-136. PubMed ID: 28077434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
    Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
    Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
    You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
    Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 101.